Capital World Investors acquired a new stake in shares of China Biologic Products Holdings Inc (NASDAQ:CBPO) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 343,304 shares of the biopharmaceutical company’s stock, valued at approximately $27,464,000. Capital World Investors owned 1.04% of China Biologic Products as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently added to or reduced their stakes in CBPO. Hsbc Holdings PLC boosted its stake in shares of China Biologic Products by 110.8% during the third quarter. Hsbc Holdings PLC now owns 1,484,839 shares of the biopharmaceutical company’s stock valued at $118,785,000 after purchasing an additional 780,455 shares during the period. Greenwoods Asset Management Ltd purchased a new stake in shares of China Biologic Products during the third quarter valued at approximately $19,600,000. FMR LLC boosted its stake in shares of China Biologic Products by 91.4% during the third quarter. FMR LLC now owns 448,094 shares of the biopharmaceutical company’s stock valued at $35,847,000 after purchasing an additional 213,994 shares during the period. Kite Lake Capital Management UK LLP purchased a new stake in shares of China Biologic Products during the third quarter valued at approximately $12,227,000. Finally, Bank of America Corp DE boosted its stake in shares of China Biologic Products by 19.8% during the second quarter. Bank of America Corp DE now owns 651,261 shares of the biopharmaceutical company’s stock valued at $64,690,000 after purchasing an additional 107,573 shares during the period. 48.63% of the stock is owned by hedge funds and other institutional investors.
Shares of China Biologic Products stock opened at $72.73 on Tuesday. The company has a market cap of $2.39 billion, a P/E ratio of 16.99, a price-to-earnings-growth ratio of 5.26 and a beta of 1.44. China Biologic Products Holdings Inc has a 52 week low of $60.08 and a 52 week high of $107.44.
China Biologic Products (NASDAQ:CBPO) last announced its earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.96 EPS for the quarter, missing analysts’ consensus estimates of $1.09 by ($0.13). The business had revenue of $119.10 million for the quarter, compared to the consensus estimate of $122.00 million. China Biologic Products had a net margin of 15.50% and a return on equity of 11.44%. China Biologic Products’s revenue was up 19.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.32 EPS. On average, research analysts expect that China Biologic Products Holdings Inc will post 3.43 EPS for the current year.
CBPO has been the subject of a number of recent analyst reports. BidaskClub downgraded China Biologic Products from a “hold” rating to a “sell” rating in a report on Friday, September 28th. Zacks Investment Research downgraded China Biologic Products from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 7th. Morgan Stanley downgraded China Biologic Products from an “overweight” rating to an “equal weight” rating and set a $84.00 target price for the company. in a report on Monday, November 5th. Finally, ValuEngine downgraded China Biologic Products from a “hold” rating to a “sell” rating in a report on Friday, August 24th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $95.33.
TRADEMARK VIOLATION WARNING: This piece of content was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://www.thelincolnianonline.com/2018/12/18/capital-world-investors-acquires-new-position-in-china-biologic-products-holdings-inc-cbpo.html.
China Biologic Products Company Profile
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Featured Article: Purposes and Functions of the Federal Reserve
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.